A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered
orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Pearl Biotechnology Limited Liability Company